Implantable cardioverter defibrillators (ICDs) are established therapy for cardiac patients at significant increased risk of sudden cardiac death. The relative risk reduction in mortality range from 23% at 5 years for primary prevention patients in the SCD-HeFT trial to 39% at one year for the secondary prevention patients in the AVID trial.
This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.
